SVA Quote, Financials, Valuation and Earnings

CASI Pharmaceuticals has a net margin of -- compared to Sinovac Biotech's net margin of -107.73%. Sinovac Biotech's return on equity of -1.05% beat CASI Pharmaceuticals's return on equity of -137%.

Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 109.79%. Given that CASI Pharmaceuticals has higher upside potential than Sinovac Biotech, analysts believe CASI Pharmaceuticals is more attractive than Sinovac Biotech.

Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals has a beta of 0.602, suggesting its less volatile than the S&P 500 by 39.83%.

Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. CASI Pharmaceuticals pays out -- of its earnings as a dividend.

Sinovac Biotech quarterly revenues are --, which are smaller than CASI Pharmaceuticals quarterly revenues of $7.8M. Sinovac Biotech's net income of -- is lower than CASI Pharmaceuticals's net income of -$8.4M. Notably, Sinovac Biotech's price-to-earnings ratio is -- while CASI Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 1.80x for CASI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holding has a net margin of -- compared to Sinovac Biotech's net margin of -101.61%. Sinovac Biotech's return on equity of -1.05% beat China Pharma Holding's return on equity of -66.27%.

Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that Sinovac Biotech has higher upside potential than China Pharma Holding, analysts believe Sinovac Biotech is more attractive than China Pharma Holding.

Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.47%.

Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

Sinovac Biotech quarterly revenues are --, which are smaller than China Pharma Holding quarterly revenues of $1.1M. Sinovac Biotech's net income of -- is lower than China Pharma Holding's net income of -$1.1M. Notably, Sinovac Biotech's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 0.54x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

LakeShore Biopharma has a net margin of -- compared to Sinovac Biotech's net margin of --. Sinovac Biotech's return on equity of -1.05% beat LakeShore Biopharma's return on equity of -7.94%.

Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand LakeShore Biopharma has an analysts' consensus of $31.51 which suggests that it could grow by 1021.4%. Given that LakeShore Biopharma has higher upside potential than Sinovac Biotech, analysts believe LakeShore Biopharma is more attractive than Sinovac Biotech.

Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LakeShore Biopharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LakeShore Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. LakeShore Biopharma pays out -- of its earnings as a dividend.

Sinovac Biotech quarterly revenues are --, which are smaller than LakeShore Biopharma quarterly revenues of --. Sinovac Biotech's net income of -- is lower than LakeShore Biopharma's net income of --. Notably, Sinovac Biotech's price-to-earnings ratio is -- while LakeShore Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 0.45x for LakeShore Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -- compared to Sinovac Biotech's net margin of -40.75%. Sinovac Biotech's return on equity of -1.05% beat Zai Lab's return on equity of -35.53%.

Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab has an analysts' consensus of -- which suggests that it could grow by 115.61%. Given that Zai Lab has higher upside potential than Sinovac Biotech, analysts believe Zai Lab is more attractive than Sinovac Biotech.

Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.26999999999999%.

Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

Sinovac Biotech quarterly revenues are --, which are smaller than Zai Lab quarterly revenues of $102.3M. Sinovac Biotech's net income of -- is lower than Zai Lab's net income of -$41.7M. Notably, Sinovac Biotech's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 6.66x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.